AR027073A1 - Ensayos y metodos de diagnostico y tratamiento basados en el uso de canales de sodio como objetivos de amiloide beta o de sus agregados - Google Patents

Ensayos y metodos de diagnostico y tratamiento basados en el uso de canales de sodio como objetivos de amiloide beta o de sus agregados

Info

Publication number
AR027073A1
AR027073A1 ARP000106865A ARP000106865A AR027073A1 AR 027073 A1 AR027073 A1 AR 027073A1 AR P000106865 A ARP000106865 A AR P000106865A AR P000106865 A ARP000106865 A AR P000106865A AR 027073 A1 AR027073 A1 AR 027073A1
Authority
AR
Argentina
Prior art keywords
aggregates
objectives
diagnosis
tests
methods
Prior art date
Application number
ARP000106865A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR027073A1 publication Critical patent/AR027073A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para identificar compuestos que modulen la interaccion del amiloide beta o sus agregados con un canal de sodio, que consista en los siguientespasos: (a) obtener una célula que incluya un canal de sodio; (b) poner en contacto el canal de sod io con el amiloide beta o sus agregados en presencia y enausencia del compuesto de ensayo; (c) determinar la accion del canal de sodio con y sin la presencia de dicho compuesto, considerando al compuesto de ensayoque ejerce un impacto sobre la activi dad como un modulador de la interaccion del amiloide beta o sus agregados con dicho canal.
ARP000106865A 1999-12-23 2000-12-21 Ensayos y metodos de diagnostico y tratamiento basados en el uso de canales de sodio como objetivos de amiloide beta o de sus agregados AR027073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17203299P 1999-12-23 1999-12-23

Publications (1)

Publication Number Publication Date
AR027073A1 true AR027073A1 (es) 2003-03-12

Family

ID=22626087

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106865A AR027073A1 (es) 1999-12-23 2000-12-21 Ensayos y metodos de diagnostico y tratamiento basados en el uso de canales de sodio como objetivos de amiloide beta o de sus agregados

Country Status (8)

Country Link
US (2) US6589747B2 (es)
EP (1) EP1240525A2 (es)
JP (1) JP2003518258A (es)
AR (1) AR027073A1 (es)
AU (1) AU2452101A (es)
CO (1) CO5271708A1 (es)
PE (1) PE20010978A1 (es)
WO (1) WO2001046700A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942963B1 (en) * 1997-01-10 2005-09-13 Massachusetts Institute Of Technology Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
EP1468293A1 (en) * 2002-01-17 2004-10-20 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of the voltage-gated ion channel scn2a for neurodegenerative diseases
JP2008544252A (ja) * 2005-06-16 2008-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経変性疾患のための潜在的薬物分子の同定における、アミロイドベータタンパク質チャネルその、構造および使用
EP2063875A2 (en) * 2007-05-01 2009-06-03 Sigmoid Pharma Limited Combination pharmaceutical compositions
CL2007002908A1 (es) * 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
WO2009111240A1 (en) * 2008-02-29 2009-09-11 Baxter International Inc. ANTI-AMYLOID β ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN VITRO
US10386360B2 (en) 2009-03-13 2019-08-20 University Of Central Florida Research Foundation, Inc. Bio-microelectromechanical system transducer and associated methods
US8815584B1 (en) 2009-04-23 2014-08-26 University Of Central Florida Research Foundation, Inc. Method of co-culturing mammalian muscle cells and motoneurons
US9163216B1 (en) 2009-04-23 2015-10-20 University Of Central Florida Research Foundation, Inc. Method for culturing skeletal muscle for tissue engineering
US8828721B1 (en) 2009-05-28 2014-09-09 University Of Central Florida Research Foundation, Inc. Method of myelinating isolated motoneurons
WO2010138679A1 (en) * 2009-05-28 2010-12-02 University Of Central Florida Research Foundation, Inc. Method of screening drugs for reversal of amyloid beta neurotoxicity
US9404140B1 (en) 2009-11-03 2016-08-02 The University Of Central Florida Research Foundation, Inc. Patterned cardiomyocyte culture on microelectrode array
US9489474B2 (en) 2010-02-05 2016-11-08 University Of Central Florida Research Foundation, Inc. Model and methods for identifying points of action in electrically active cells
CA2798777C (en) 2010-04-23 2016-09-06 University Of Central Florida Research Foundation, Inc. Formation of neuromuscular junctions in a defined system
DE102010063457A1 (de) 2010-12-17 2012-06-21 Henkel Ag & Co. Kgaa Lagerstabiles flüssiges Wasch- oder Reinigungsmittel enthaltend Protease und Cellulase
DE102010063743A1 (de) 2010-12-21 2012-06-21 Henkel Ag & Co. Kgaa Flüssige Tensidzubereitung enthaltend Lipase und Phosphonat
DE102011007313A1 (de) 2011-04-13 2012-10-18 Henkel Ag & Co. Kgaa Expressionsverfahren
DE102011007627A1 (de) 2011-04-18 2012-10-18 Henkel Ag & Co. Kgaa Wasch- oder Reinigungsmittel mit fester Enzymkonfektionierung
DE102011007695A1 (de) 2011-04-19 2012-10-25 Henkel Ag & Co. Kgaa Phosphatfreies Geschirrspülmittel
DE102011118032A1 (de) 2011-05-31 2012-12-06 Henkel Ag & Co. Kgaa Expressionsvektoren zur verbesserten Proteinsekretion
DE102011118037A1 (de) 2011-06-16 2012-12-20 Henkel Ag & Co. Kgaa Geschirrspülmittel mit Bleichkatalysator und Protease
DE102012201297A1 (de) 2012-01-31 2013-08-01 Basf Se Expressionsverfahren
DE102012206571A1 (de) 2012-04-20 2013-10-24 Henkel Ag & Co. Kgaa Lagerstabiles Wasch- oder Reinigungsmittel mit gesteigerter Reinigungsleistung
EP2885394A4 (en) 2012-08-17 2016-04-20 Univ Central Florida Res Found METHODS, SYSTEMS, AND COMPOSITIONS FOR FUNCTIONAL IN VITRO CELLULAR MODELS OF MAMMALIAN SYSTEMS
DE102012215107A1 (de) 2012-08-24 2014-02-27 Basf Se Festes Geschirrspülmittel mit verbesserter Proteaseleistung
DE102012224038A1 (de) 2012-12-20 2014-06-26 Henkel Ag & Co. Kgaa Enzymhaltige Granulatzusammensetzung
CA2899445C (en) 2013-01-30 2023-04-04 University Of Central Florida Research Foundation, Inc. Devices and systems for mimicking heart function
DE102013226835A1 (de) 2013-12-20 2015-06-25 Henkel Ag & Co. Kgaa Wasch- oder Reinigungsmittel mit reduziertem Tensidgehalt
US10935541B2 (en) 2014-08-07 2021-03-02 University Of Central Florida Research Foundation, Inc. Devices and methods comprising neuromuscular junctions
DE102014225478A1 (de) * 2014-12-10 2016-06-16 Henkel Ag & Co. Kgaa Wasch- oder Reinigungsmittel mit spezieller a-Amylase und definierter Wasseraktivität aw
DE102014225475A1 (de) 2014-12-10 2016-06-16 Henkel Ag & Co. Kgaa Wasch- oder Reinigungsmittel mit spezieller a-Amylase und definierter Viskosität
DE102014226293A1 (de) 2014-12-17 2016-06-23 Henkel Ag & Co. Kgaa Waschmittel mit verbesserter Fleckentfernung
DE102014226681A1 (de) 2014-12-19 2016-06-23 Henkel Ag & Co. Kgaa Flüssige Tensidzusammensetzung mit spezieller Tensidkombination und Enzym
DE102015215158A1 (de) 2015-08-07 2017-02-09 Henkel Ag & Co. Kgaa Neue, den Weißgrad verstärkende Waschmittel
DE102015215160A1 (de) 2015-08-07 2017-02-09 Henkel Ag & Co. Kgaa Neue den Weißgrad verstärkende Waschmittel
DE102015215163A1 (de) 2015-08-07 2017-02-09 Henkel Ag & Co. Kgaa Waschmittel mit Bügelhilfsmittel
DE102015215591A1 (de) 2015-08-14 2017-02-16 Henkel Ag & Co. Kgaa Wasserarme, zweiphasige Flüssigwaschmittel mit saurem pH-Wert
DE102016213568A1 (de) 2016-07-25 2018-01-25 Henkel Ag & Co. Kgaa Polymere aus Vinylpyrrolidon und/oder Vinylacetat als textilpflegende Inhaltsstoffe
DE102016213567A1 (de) 2016-07-25 2018-01-25 Henkel Ag & Co. Kgaa Propylenglykolester als textilpflegende Inhaltsstoffe
DE102016213569A1 (de) 2016-07-25 2018-01-25 Henkel Ag & Co. Kgaa Acylglutamate als textilpflegende Inhaltsstoffe
DE102016221849A1 (de) 2016-11-08 2018-05-09 Henkel Ag & Co. Kgaa Tensidzusammensetzung enthaltend eine Amylase
WO2018099762A1 (en) 2016-12-01 2018-06-07 Basf Se Stabilization of enzymes in compositions
US10385291B2 (en) 2016-12-22 2019-08-20 Henkel Ag & Co. Kgaa Liquid surfactant compositions and associated methods
US10047321B2 (en) 2016-12-22 2018-08-14 Henkel Ag & Co. Kgaa Liquid surfactant compositions having a modified oxo-alcohol derivative
EP3412761A1 (en) 2017-06-07 2018-12-12 Henkel AG & Co. KGaA Anti-pilling laundry sheet
DE102017215015A1 (de) 2017-08-28 2019-02-28 Henkel Ag & Co. Kgaa Verfahren zur verbesserten Expression von Enzymen
WO2019206994A1 (en) 2018-04-26 2019-10-31 Basf Se Lipase enzymes
DE102018217397A1 (de) 2018-10-11 2020-04-16 Henkel Ag & Co. Kgaa Verwendung von übergangsmetallfreien Abtönungsfarbstoffen in Kombination mit Catecholderivaten
DE102018217393A1 (de) 2018-10-11 2020-04-16 Henkel Ag & Co. Kgaa Waschmittelzusammensetzung mit Catechol-Metallkomplexverbindung
DE102018217399A1 (de) 2018-10-11 2020-04-16 Henkel Ag & Co. Kgaa Flüssige Zusammensetzung mit Dihydroxyterephthalsäurediamid-Verbindung und hoher Tensidmenge
DE102018217392A1 (de) 2018-10-11 2020-04-16 Henkel Ag & Co. Kgaa Mehrkomponenten-Waschmittel mit Catechol-Metallkomplex
DE102018217398A1 (de) 2018-10-11 2020-04-16 Henkel Ag & Co. Kgaa Flüssigwaschmittel mit Dihydroxyterephthalsäurediamid-Verbindung
EP3666872B1 (en) 2018-12-12 2021-08-11 Henkel AG & Co. KGaA Phosphonated acrylic copolymers for surface hydrophilization
DE102019204792A1 (de) 2019-04-04 2020-10-08 Henkel Ag & Co. Kgaa Verwendung von Mannanase-Enzym in Kombination mit Catecholderivaten
WO2021105336A1 (en) 2019-11-29 2021-06-03 Basf Se Compositions comprising polymer and enzyme
CN116096731A (zh) 2020-09-22 2023-05-09 巴斯夫欧洲公司 蛋白酶和蛋白酶抑制剂与第二酶的改进的组合
DE102021100563A1 (de) 2021-01-13 2022-07-14 Henkel Ag & Co. Kgaa Parfüm- und enzym-haltige zusammensetzung
WO2023117992A1 (en) 2021-12-21 2023-06-29 Basf Se Environmental attributes for aqueous polymeric composition
WO2024033136A1 (en) 2022-08-11 2024-02-15 Basf Se Amylase variants
WO2024033135A2 (en) 2022-08-11 2024-02-15 Basf Se Amylase variants
WO2024094735A1 (en) 2022-11-04 2024-05-10 Basf Se Polypeptides having protease activity for use in detergent compositions
WO2024094733A1 (en) 2022-11-04 2024-05-10 Basf Se Polypeptides having protease activity for use in detergent compositions
WO2024094732A1 (en) 2022-11-04 2024-05-10 Basf Se Polypeptides having protease activity for use in detergent compositions
EP4389864A1 (en) 2022-12-20 2024-06-26 Basf Se Cutinases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5137873A (en) 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
AU3440593A (en) * 1993-01-14 1994-08-15 Nelson Arispe Methods and compositions for blocking amyloid protein ion channels
US5892018A (en) 1996-04-02 1999-04-06 Welsh; Michael J. DNA sequences encoding a brain sodium channel protein
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
EP0884386A1 (en) 1997-05-30 1998-12-16 Synthelabo Sodium channel receptor

Also Published As

Publication number Publication date
JP2003518258A (ja) 2003-06-03
WO2001046700A2 (en) 2001-06-28
WO2001046700A3 (en) 2001-12-27
PE20010978A1 (es) 2001-09-14
US20020004194A1 (en) 2002-01-10
US6589747B2 (en) 2003-07-08
CO5271708A1 (es) 2003-04-30
US20030211542A1 (en) 2003-11-13
AU2452101A (en) 2001-07-03
EP1240525A2 (en) 2002-09-18

Similar Documents

Publication Publication Date Title
AR027073A1 (es) Ensayos y metodos de diagnostico y tratamiento basados en el uso de canales de sodio como objetivos de amiloide beta o de sus agregados
ES2054649T3 (es) 2-aminotetralinas basicas substituidas.
AR029583A1 (es) Diagnostico precoz de enfermedades de conformacion
ES2190727B1 (es) Dispositivo para formar y/o aumentar el numero relativo de celulas indiferenciadas en una poblacion celular y procedimientos correspondientes.
ES2161442T3 (es) Analogos de coralina como inhibidores de topoisomerasa.
ES2112829T3 (es) Procedimiento y aparato para reactivar un electrodo de un biosensor.
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
GT200600407A (es) Compuestos ppar activos
HUP0001261A2 (hu) Eljárás az in vivo bekövetkező sejthalál leképezésére
BR9711139A (pt) Elementos de teste de ph e amina e aplicações para diagnose de infecções vaginais.
ES2138853T3 (es) Composicion de teñido por oxidacion para fibras queratinicas que comprenden un polimero anfifilo anionico.
AR039768A1 (es) Virus oncoliticos como agentes de determinacion del fenotipo de neoplasmas
EA200000351A1 (ru) Лечение кондуктивных нарушений
ES2130686T3 (es) Procedimiento para la preparacion de metalocenil-fosfinas opticamente activas.
ES2133727T3 (es) Derivados de acido hidroxamico como inhibidores de metaloproteinasa.
ATE268904T1 (de) Zellbasiertes festphasentest
AR011557A1 (es) Un medio de cultivo y metodos para detectar estafilococos
AR015837A1 (es) Metodo de transformacion de plantas.
ES2172264T3 (es) Nuevos derivados del p-diamino-benceno adecuados para el teñido de fibras de queratina.
AR048135A1 (es) Uso de gen de amiloide a serico en el diagnostico y tratamiento del glaucoma y en la identificacion de agentes anti-glaucoma.
ES2079438T5 (es) Lubricante esterilizable.
BR0011741A (pt) Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear
UY39744A (es) Composición farmacéutica que comprende un agonista de gpr40 y un inhibidor de sglt-2
AR022861A1 (es) Un dispositivo de analisis que incluye discos con almohadilla de inoculacion y metodos de uso
ES503650A0 (es) Procedimiento para la trimetilsililacion de compuestos organicos que llevan uno o mas atomo de hidrogeno activo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure